Aratana Therapeutics Inc (NASDAQ:PETX) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 15, 2016
Boasting a price of $9.09, Aratana Therapeutics Inc (NASDAQ:PETX) traded -5.54% lower on the day. With the last stock price close up 14.04% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Aratana Therapeutics Inc has recorded a 50-day average of $9.27 and a two hundred day average of $7.48. Volume of trade was up over the average, with 837,993 shares of PETX changing hands over the typical 809,063
Zacks Investment Research has downgraded Aratana Therapeutics Inc (NASDAQ:PETX) to Sell in a statement released on 10/13/2016.
On Tuesday September 06, 2016, Lake Street released a statement for Aratana Therapeutics Inc (NASDAQ:PETX) bumped up the target price from $0.00 to $15.00 that suggested an upside of 0.64%.
With a total market value of $0, Aratana Therapeutics Inc has with a one year low of $2.56 and a one year high of $10.73 .
A total of 7 equity analysts have released a research note on PETX. Three equity analysts rating the company a strong buy, five equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $12.29.
Brief Synopsis About Aratana Therapeutics Inc (NASDAQ:PETX)
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.